Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review.

Biochemical recurrence Evidence synthesis Nerve-sparing radical prostatectomy Oncological outcome Positive surgical margins Prostate cancer Systematic review

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
05 2022
Historique:
received: 22 03 2021
revised: 10 04 2021
accepted: 25 05 2021
pubmed: 21 6 2021
medline: 1 9 2022
entrez: 20 6 2021
Statut: ppublish

Résumé

Surgical techniques aimed at preserving the neurovascular bundles during radical prostatectomy (RP) have been proposed to improve functional outcomes. However, it remains unclear if nerve-sparing (NS) surgery adversely affects oncological metrics. To explore the oncological safety of NS versus non-NS (NNS) surgery and to identify factors affecting the oncological outcomes of NS surgery. Relevant databases were searched for English language articles published between January 1, 1990 and May 8, 2020. Comparative studies for patients with nonmetastatic prostate cancer (PCa) treated with primary RP were included. NS and NNS techniques were compared. The main outcomes were side-specific positive surgical margins (ssPSM) and biochemical recurrence (BCR). Risk of bias (RoB) and confounding assessments were performed. Out of 1573 articles identified, 18 studies recruiting a total of 21 654 patients were included. The overall RoB and confounding were high across all domains. The most common selection criteria for NS RP identified were characteristic of low-risk disease, including low core-biopsy involvement. Seven studies evaluated the link with ssPSM and showed an increase in ssPSM after adjustment for side-specific confounders, with the relative risk for NS RP ranging from 1.50 to 1.53. Thirteen papers assessing BCR showed no difference in outcomes with at least 12 mo of follow-up. Lack of data prevented any subgroup analysis for potentially important variables. The definitions of NS were heterogeneous and poorly described in most studies. Current data revealed an association between NS surgery and an increase in the risk of ssPSM. This did not translate into a negative impact on BCR, although follow-up was short and many men harbored low-risk PCa. There are significant knowledge gaps in terms of how various patient, disease, and surgical factors affect outcomes. Adequately powered and well-designed prospective trials and cohort studies accounting for these issues with long-term follow-up are recommended. Neurovascular bundles (NVBs) are structures containing nerves and blood vessels. The NVBs close to the prostate are responsible for erections. We reviewed the literature to determine if a technique to preserve the NVBs during removal of the prostate causes worse cancer outcomes. We found that NVB preservation was poorly defined but, if applied, was associated with a higher risk of cancer at the margins of the tissue removed, even in patients with low-risk prostate cancer. The long-term importance of this finding for patients is unclear. More data are needed to provide recommendations.

Identifiants

pubmed: 34147405
pii: S2405-4569(21)00161-9
doi: 10.1016/j.euf.2021.05.009
pii:
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

690-700

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Lisa Moris (L)

Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: lisa.moris1506@gmail.com.

Giorgio Gandaglia (G)

Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Antoni Vilaseca (A)

Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Thomas Van den Broeck (T)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Erik Briers (E)

Patient Advocate, Hasselt, Belgium.

Maria De Santis (M)

Department of Urology, Charité University Hospital Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.

Silke Gillessen (S)

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.

Nikos Grivas (N)

Department of Urology, Hatzikosta General Hospital, Ioannina, Greece.

Shane O'Hanlon (S)

Medicine for Older People, Saint Vincent's University Hospital, Dublin, Ireland.

Ann Henry (A)

Leeds Cancer Centre, St. James's University Hospital and University of Leeds, Leeds, UK.

Thomas B Lam (TB)

Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.

Michael Lardas (M)

Department of Urology, Metropolitan General Hospital, Athens, Greece.

Malcolm Mason (M)

Division of Cancer & Genetics, School of Medicine Cardiff University, UK.

Daniela Oprea-Lager (D)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Guillaume Ploussard (G)

La Croix du Sud Hospital, Quint Fonsegrives, France.

Olivier Rouviere (O)

Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Ivo G Schoots (IG)

Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Henk van der Poel (H)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Thomas Wiegel (T)

Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.

Peter-Paul Willemse (PP)

Department of Oncological Urology, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Cathy Y Yuan (CY)

Department of Medicine, Health Science Centre, McMaster University, Hamilton, ON, Canada.

Jeremy P Grummet (JP)

Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Roderick C N van den Bergh (RCN)

Department of Urology, Antonius Hospital, Utrecht, The Netherlands.

Philip Cornford (P)

Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK.

Nicolas Mottet (N)

Department of Urology, University Hospital, St. Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH